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Background: Postnatal corticosteroids are used to improve lung function and reduce the incidence of
bronchopulmonary dysplasia (BPD) in preterm babies. However, corticosteroids may be associated with
adverse neurodevelopment. Despite a lack of evidence, some clinicians in the UK use very low-dose
regimens of dexamethasone hoping for positive pulmonary effects and optimal neurodevelopment.
Objectives: To assess the efficacy and safety of very low-dose dexamethasone at facilitating the extubation
of ventilator-dependent preterm babies born at < 30 weeks’ gestation and who are at high risk of developing
BPD.
Design: A multicentre, randomised, masked, parallel-group, placebo-controlled Phase 2b trial. The trial
was designed as a feasibility study for a subsequent trial of clinical effectiveness.
Setting: The study was set in 11 tertiary neonatal units in the UK.
Participants: Ventilator-dependent preterm babies born at < 30 weeks’ gestation aged 10–21 days,
receiving at least 30% inspired oxygen and at high risk of developing BPD. Exclusions were babies who
had received previous courses of postnatal steroids for respiratory disease; had a severe congenital
anomaly affecting the lungs, heart or central nervous system, or had a surgical abdominal procedure or
patent ductus arteriosus ligation; and had an illness or medication for which postnatal corticosteroid would
be contraindicated (e.g. confirmed or suspected acute sepsis, acute necrotising enterocolitis/focal intestinal
perforation or cyclo-oxygenase therapy).
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Interventions: Babies were randomised to very low-dose dexamethasone (50 µg/kg/day for 13 doses) or a
matched placebo. Samples of blood and bronchoalveolar lavage fluid from a subset of babies randomised
at three participating sites were sent for cytokine analysis at randomisation and at days 5, 7, 10 and 14 of
treatment.
Primary outcome: Time to extubation.
Secondary outcomes: Secondary outcomes included rates of extubation by day 7 of the intervention;
survival to 36 weeks’ postmenstrual age (PMA) or discharge home; respiratory morbidity to 36 weeks’
PMA or discharge home; cytokine profile; safety outcomes; and parent/family experience.
Results: The main metric of feasibility, namely recruitment, proved difficult. There was a tendency for open-
label medication and a higher than predicted rate of suspected/confirmed sepsis among babies. Recruitment
was halted after 22 babies had been enrolled. It was found that, compared with the placebo group, a higher
proportion of babies were extubated at day 7 of life [5/8 (62.5%) in the very low-dose dexamethasone
group vs. 2/6 (33.3%) in the placebo group] and duration of invasive ventilation was lower (a median of
23 days for the very low-dose dexamethasone group vs. a median of 31 days for the placebo group) in the
very low-dose dexamethasone group. This is supported by a trend for an increased requirement for open-
label rescue steroids in control group babies (41.7% in the very low-dose dexamethasone group vs. 80% in
the placebo group). Given the limited sample size, only descriptive statistics can be given; firm conclusions
cannot be drawn.
Limitations: Small sample size and high rates of open-label treatment use.
Conclusions: It is not feasible to conduct the required pragmatic trial of clinical effectiveness.
Future work: Assessment of very low-dose dexamethasone in this patient group requires careful
consideration.
Study registration: Clinical Controlled Trials ISRCTN81191607.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a
Medical Research Council and National Institute for Health Research (NIHR) partnership. The report will be
published in full in Efficacy and Mechanism; Vol. 6, No. 8. See the NIHR Journals Library website for further
project information. The funding for the cytokine analysis is provided by the Children’s Charity Cerebra
and is being carried out beyond the lifespan of the NIHR funding.
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VEGF vascular endothelial growth factor
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Babies born prematurely who require prolonged support with breathing machines through a breathingtube (i.e. mechanical ventilation) are at an increased risk of developing long-term breathing problems
because of a condition called bronchopulmonary dysplasia (BPD), sometimes called chronic lung disease.
Babies with BPD have an increased risk of learning difficulties and cerebral palsy (CP).
Dexamethasone has been used to help babies get off mechanical ventilation. However, previous research
shows that babies who are given large doses of dexamethasone and given dexamethasone in the first week
of life have an increased risk of CP and learning difficulties. The benefits of the use of dexamethasone in
babies with a low risk of developing BPD is outweighed by an increased risk of developmental delay.
Neonatologists now tend to use only low or very low doses of dexamethasone in babies older than 1 week of
age, who are at high risk of developing BPD. There is no clear evidence to support this. To plan the research
needed to inform practice, evidence was required to suggest that giving a very small dose of dexamethasone
to a baby who is dependent on a ventilator will improve their lungs enough to allow the breathing tube to be
removed.
This trial asked whether or not giving a very small dose of dexamethasone to a baby born at ≤ 30 weeks’
gestation who is ‘stuck’ on a ventilator and at high risk of BPD will help the baby come off the ventilator.
Babies were allocated randomly to receive dexamethasone or a dummy medicine (i.e. a placebo). Their
breathing outcomes and side effects were compared. A few babies had assessments carried out on very
small blood samples or breathing tube fluid samples to help to see what effects the dexamethasone has
on the lungs.
There were fewer babies suitable to participate in the trial than anticipated, so recruitment was poor.
The funder decided to stop recruitment. The study was not able to answer the research questions.
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Bronchopulmonary dysplasia (BPD) poses a significant health-care burden for babies born prematurely,
adversely affecting both long-term respiratory and neurodevelopmental outcomes. Postnatal corticosteroids
have been used to improve lung function and reduce the incidence of BPD [relative risk (RR) 0.77, 95%
confidence interval (CI) 0.67 to 0.88], yet concerns were raised that postnatal corticosteroids may be
associated with adverse long-term neurological outcomes when a meta-analysis published a cerebral palsy
RR of 1.92 (95% CI 1.41 to 2.61).
Further analysis of the available evidence led to the discovery that the adverse neurodevelopmental outcomes
were associated with treating babies in the first 7 days of life with dexamethasone, treating babies at a
low risk of developing BPD with corticosteroids, and treating babies with high doses (i.e. a cumulative dose
> 3.0 mg/kg) of dexamethasone.
These findings have resulted in many clinicians in the UK treating babies older than 1 week of age, who are
deemed to be at high risk of developing BPD, with very low-dose regimens of dexamethasone in the hope
that the beneficial pulmonary effects will be seen, and the baby is spared from adverse neurodevelopmental
outcomes. There is no clear evidence to support this use of very low-dose dexamethasone.
Objectives
The objective of the study was to assess the efficacy of very low-dose dexamethasone at facilitating the
extubation of ventilator-dependent preterm babies born at < 30 weeks’ gestation and who are at high risk
of developing BPD.
Research questions
1. How effective is very low-dose dexamethasone at reducing the duration of invasive intermittent
positive-pressure ventilation in ventilator-dependent preterm babies born at < 30 weeks’ gestation and
who are at high risk of developing BPD?
2. What is the safety of very low-dose dexamethasone?
– Does very low-dose dexamethasone increase the risk of adverse effects that are seen with high-dose
dexamethasone, for example hypertension, hyperglycaemia, confirmed/suspected sepsis and
gastrointestinal perforation/necrotising enterocolitis?
– Does very low-dose dexamethasone therapy result in changes in babies’ cranial ultrasound scans
between randomisation and 36 weeks’ postmenstrual age (PMA)?
– Does very low-dose dexamethasone therapy result in changes in babies’ neonatal growth?
3. Will it be possible to perform a large multicentre randomised controlled trial to assess the 2-year
neurodevelopmental outcomes of treatment with very low-dose dexamethasone?
4. Is a novel assessment of the family’s involvement with their baby feasible?
5. Does very low-dose dexamethasone affect changes in babies’ biochemical inflammatory
cytokine profile?
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Methods
This was a multicentre, randomised, masked, parallel-group, placebo-controlled Phase 2b trial.
The trial was designed as a feasibility study for a subsequent study of the clinical effectiveness of very
low-dose dexamethasone in reducing the incidence of BPD at 36 weeks’ PMA. As such, the study had a




l babies born at < 30 weeks’ gestation
l babies aged between 10 and 24 postnatal days (i.e. ≥ 10 and ≤ 24 postnatal days)
l babies at high risk of developing BPD – receiving mechanical ventilation, via an endotracheal tube,
receiving at least 30% inspired oxygen when the positive end-expiratory pressure is at least 4 cmH2O
and, in the opinion of the treating physician, unlikely to be extubated within 48 hours
l babies receiving caffeine therapy
l written informed parental consent
l babies born to a mother aged ≥ 16 years.
Exclusion criteria
Exclusion criteria included babies:
l receiving postnatal steroid treatment for prevention or treatment of respiratory disease
l with no realistic prospect of survival
l with a severe congenital anomaly affecting the lungs, heart or central nervous system
l having undergone a surgical abdominal procedure or patent ductus arteriosus ligation
l who are ill or receiving medication for which postnatal corticosteroid would be contraindicated
(e.g. an active fungal infection, confirmed or suspected acute sepsis, acute necrotising enterocolitis/focal
intestinal perforation or cyclo-oxygenase therapy)
l participating in another trial that would preclude the baby from inclusion in the MINIDEX feasibility trial.
Babies were recruited from 11 UK neonatal units and randomised (1 : 1) to the active intervention
[once-daily 50 µg/kg dexamethasone on days 1–10 after randomisation (i.e. 10 doses), then dexamethasone
was given on alternate days (i.e. on days 12, 14 and 16), making a total of 13 doses (a cumulative dose
0.65 mg/kg)] or a matched saline placebo.
Data were collected on the case report form at trial entry, daily throughout Investigative Medicinal Product
administration and at 36 weeks’ PMA.
Results
The trial was delayed in starting and, once open, recruitment was lower than predicted because of a
shortage of eligible babies. After 9 months of recruiting, 22 babies of the planned sample size of 94, had
been randomised to the trial. There was a higher than anticipated discontinuation rate among the recruited
babies (i.e. 12 babies of the 22 randomised were discontinued, 11 of them for confirmed/suspected sepsis or
requirement for open-label steroid therapy). Following this poor recruitment and high discontinuation rate
the funder decided to stop recruitment. It was agreed that the final report should provide only a descriptive
analysis because of the small number of babies recruited to the trial.
SCIENTIFIC SUMMARY
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It is not possible to report the primary outcome; however, a few secondary outcomes can be given as
descriptive statistics. It was found that, compared with the placebo group, a higher proportion of babies
extubated were at day 7 of life [5/8 (62.5%) for the very low-dose dexamethasone group vs. 2/6 (33.3%)
for the placebo group] and a reduced duration of invasive ventilation (a median of 23 days in the very
low-dose dexamethasone group vs. a median of 31 days in the placebo group) in the very low-dose
dexamethasone group. This is supported by a trend for an increased requirement for open-label rescue
steroids in control group babies (41.7% in the very low-dose dexamethasone group vs. 80% in the
placebo group).
Conclusions
The trial addressed the question of whether or not giving very low-dose dexamethasone to ventilator-
dependent preterm babies < 30 weeks’ gestation facilitates extubation. The trial used a surrogate outcome
and was designed to facilitate the design of a definitive large pragmatic trial using substantive outcomes.
The MINIDEX trial has made it clear that in the contemporary clinical context it is not possible to recruit to
a large pragmatic trial of very low-dose dexamethasone that would give the substantive outcomes needed
to inform clinical practice. The research question remains open.
Future work
Assessment of very low-dose dexamethasone in this patient group requires careful consideration.
Study registration
The study is registered with the International Standard Randomised Controlled Trial Number (ISRCTN)
registry as number ISRCTN81191607.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research (NIHR) partnership. The funding for the cytokine analysis is
provided by the Children’s Charity Cerebra and is being carried out beyond the lifespan of the NIHR funding.
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Bronchopulmonary dysplasia (BPD) affects approximately 25% of all babies born at < 30 weeks’ gestation1,2
and represents a significant health-care burden. Few interventions are proven to reduce BPD incidence or
severity.3 Babies who develop BPD are at increased risk of long-term respiratory and neurodevelopmental
impairment.4,5 Natarajan et al. reported that 7% of survivors with BPD had moderate to severe cerebral palsy
(CP) and 11.4% had severely abnormal neurodevelopmental outcomes [i.e. composite cognitive scores on
Bayley Scales of Infant and Toddler Development III (BSID-III) of < 70 points].5 These outcomes are seen in
only 2% and 4.6% of matched babies without BPD in the study by Natarajan et al.5 When these outcomes
are combined (to account for comorbidity) the results suggest that 200 babies per annum in the UK develop
moderate or severe disability solely attributable to BPD.5 Therapies like postnatal corticosteroids, which
reduce the burden of BPD, will therefore reduce the burden of neurodevelopmental and respiratory
impairment that BPD entails.
Since the 1970s, postnatal corticosteroids have been used in a variety of dose regimens to ameliorate the
lungs’ inflammatory responses and reduce the incidence of BPD.6–8 Babies with BPD exhibit a variety of
inflammatory biomarkers and numerous cytokines are implicated in the evolution of the disease.9–11
Postnatal corticosteroids have been found to downregulate many proinflammatory cytokines in these
babies12 and have been shown in meta-analyses to facilitate the extubation of preterm babies and reduce
the incidence of BPD.6,7 The most recent Cochrane review of late administration of corticosteroids (in
infants > 7 days of age) shows that corticosteroids were associated with a lower rate of failure to extubate
by the seventh day of treatment [risk ratio 0.65, 95% confidence interval (CI) 0.59 to 0.72] and reduction
of the incidence of BPD (risk ratio 0.77, 95% CI 0.67 to 0.88).7 As a result of these benefits, postnatal
corticosteroid therapy became commonplace. In 1995, 72.5% of all surviving babies born at < 26 weeks’
gestation in the UK received postnatal corticosteroids.13
Concerns about the long-term neurodevelopmental impact of postnatal corticosteroids were first raised
in 1974,8 but it was in 2001 that Barrington’s meta-analysis showed that babies treated with postnatal
corticosteroids have an increased risk of long-term adverse neurodevelopmental outcomes (CP: RR 1.92, 95% CI
1.41 to 2.61).14 In addition to this, studies in animals have shown that postnatal exposure to corticosteroids
during the critical period of late neurogenesis can impair myelination and neuronal maturation.15–17 As a
result of these findings, postnatal corticosteroids became less popular with clinicians18 and their use declined
dramatically. This in turn resulted in an increased prevalence of BPD.19
Further investigation of the relationship between postnatal corticosteroids, BPD and neurodevelopmental
impairment has shown that the relationship between corticosteroids and neurodevelopmental outcomes is
complex and poorly understood. Meta-analyses have revealed that the risk of adverse neurodevelopmental
outcome is modified by the corticosteroid used,6 the postnatal age at which the corticosteroids are given,6 7
the cumulative dose used20 and the baby’s underlying risk of developing BPD21 (Table 1). An increased risk
of adverse outcomes is seen only in those trials that include babies:
l treated with dexamethasone at < 7 days of age to prevent BPD (CP: RR 1.75, 95% CI 1.2 to 2.55)6
l exposed to high doses (i.e. a > 3.0 mg/kg cumulative dose) of dexamethasone [CP: odds ratio (OR) 2.3,
95% CI 1.22 to 4.36]20
l treated with postnatal corticosteroids who are at low risk of developing BPD.21
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Hydrocortisone has been used to prevent BPD in babies < 7 days of age and, although it is not associated
with an increased risk of cerebral palsy (CP: RR 1.05, 95% CI 0.66 to 1.66), hydrocortisone treatment does
not reduce the risk of BPD (BPD: RR 0.91, 95% CI 0.8, 1.05).6 To date, there has been only one published
study giving hydrocortisone to 64 ventilator-dependent babies aged 10–14 days,22 this is combined with
20 trials (1360 babies) with an arm that was randomised to dexamethasone in the meta-analysis results in
Table 1.
No increased risk of adverse neurodevelopment or CP was seen in those trials that use corticosteroids in
babies:
l over 7 days of age to treat established or evolving BPD (CP: RR 1.1, 95% CI 0.77 to 1.56)7
l exposed to lower doses of dexamethasone (CP: OR 0.61, 95% CI 0.28 to 1.34)20
l at high risk of BPD (control rates of BPD of c. 65%).21
It was calculated that every 10% increase in babies BPD rate reduces the risk difference of CP by 2.4%
(95% CI 0.3% to 4.3%).21
To reduce the risk of adverse neurodevelopmental outcomes while maintaining the beneficial pulmonary
effects, many clinicians across the UK looked to using low-dose (i.e. a ≤ 3.0 mg/kg cumulative dose) and
very low-dose (i.e. a ≤ 1.5 mg/kg cumulative dose) regimens of dexamethasone in babies over 8 days of
age at high risk of BPD.23 In Belfast, from 2004, very low-dose dexamethasone was used to treat ventilator-
dependent babies with BPD,24 although any reported benefits were not based on randomised trials. Another
tertiary unit introduced the Minidex protocol.25 The Minidex regimen is 50 µg/kg/day dexamethasone every day
for 10 days, then on alternate days for 6 days. The regimen was derived from the physiological corticosteroid
replacement dose and is lower than the next lowest dose regimen that has been subjected to short-term
assessment.26 Leeds Teaching Hospitals Trust published its results as a retrospective cohort study.25 This
report showed that babies treated with this regimen were extubated significantly faster than control babies,
with a hazard ratio (HR) of 6.24 (95% CI 2.34 to 16.63).25
There is insufficient evidence to support these very low-dose regimens of dexamethasone.20 No very
low-dose regimen of dexamethasone has been subjected to a randomised controlled trial that was
adequately powered to detect neurodevelopmental outcomes.
TABLE 1 Summary of findings of meta-analyses
Administration and dose
Condition
CP BPD at 36 weeks’ PMA
Administration, RR (95% CI)
Early (< 8 days) administration of dexamethasone6 1.75 (1.2 to 2.55) 0.71 (0.62 to 0.81)
Early (< 8 days) administration of hydrocortisone6 1.05 (0.66 to 1.66) 0.91 (0.8 to 1.05)
Late (> 7 days) administration of corticosteroid7 1.1 (0.79 to 1.54) 0.77 (0.67 to 0.88)
Dose, OR (95% CI)
Low cumulative dose (i.e. < 3.0 mg/kg) of dexamethasone20 0.61 (0.28 to 1.34) 0.66 (0.54 to 0.8)
High cumulative dose (i.e. ≥ 3.0 mg/kg) of dexamethasone20 2.3 (1.22 to 4.36) 0.34 (0.2 to 0.57)
PMA, postmenstrual age.
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Rationale
There is no definitive evidence of the impact of very low-dose dexamethasone on clinically important
outcomes, size of effect or safety. An effectiveness trial aimed at establishing the 2-year neurodevelopmental
outcomes of babies receiving the Minidex regimen is needed to inform practice. However, prior to this, a
smaller study to determine short-term clinical efficacy, acceptability, recruitment and retention is necessary to
allow the definitive trial to be planned. The MINIDEX trial was designed to meet the need for a preliminary
efficacy study and, in December 2014, was funded by the National Institute for Health Research (NIHR)
Efficacy and Mechanism Evaluation (EME) programme. In this efficacy study, extubation and respiratory
morbidity prior to hospital discharge were used as surrogate outcomes for the clinically relevant outcome of
long-term respiratory morbidity.
If the treatment ultimately proves to be effective, it will benefit patients by improving pulmonary function
and facilitating extubation, thereby reducing both the duration of invasive ventilation and the risk of
adverse long-term respiratory outcomes. Clinical trials are justified to assess the benefit–risk balance for
this therapy. The trial participants are limited exclusively to those babies deemed to be at high risk of BPD.
The meta-regression by Doyle et al. suggests that the risk of neurodevelopmental impairment attributable
to a low dose of corticosteroids for the participants in this trial should be minimal.21 Should the therapy be
shown not to facilitate extubation, then it can be recommended that the off-label use of very low-dose
dexamethasone for this indication is discontinued. This would save babies across the UK from unnecessary
exposure to a potential neurotoxin.
Family involvement in care is important, that is, being actively involved in the baby’s day-to-day care and
having contact with their child is an important part of both parental bonding and baby development.27 It is
hypothesised that improved clinical stability of the baby will facilitate increased family involvement in the
baby’s care and improve developmental care. Therefore, piloting an assessment tool that could measure
the extent of family involvement is wished for.
Collection of cytokine profiles in a subset of the babies will expand scientific knowledge of the processes
involved and generate mechanistic hypotheses. One possibility is that cytokine profiles may make it possible
to identify babies who are likely to respond to corticosteroids and those who are likely to be non-responders.
If non-responders can be identified, it may be possible to target therapy avoiding unnecessary exposure.
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Chapter 2 Research objectives
Aim
The aim of the study was to assess the efficacy of very low-dose dexamethasone in facilitating the
extubation of ventilator-dependent preterm babies born at < 30 weeks’ gestation who are at high risk of
developing BPD.
Hypothesis
Administration of very low-dose dexamethasone to premature babies who are dependent on intermittent
positive-pressure respiratory support, via endotracheal intubation, will facilitate extubation.
Research questions
1. How effective is very low-dose dexamethasone at reducing the duration of invasive intermittent
positive-pressure ventilation in ventilator-dependent preterm babies born at < 30 weeks’ gestation
who are at high risk of developing BPD?
2. What is the safety of very low-dose dexamethasone?
– Does very low-dose dexamethasone increase the risk of adverse effects that are seen with high-dose
dexamethasone, for example hypertension, hyperglycaemia, confirmed/suspected sepsis,
gastrointestinal perforation/necrotising enterocolitis (NEC)?
– Does very low-dose dexamethasone therapy result in changes in babies’ cranial ultrasound scans
between randomisation and 36 weeks’ postmenstrual age (PMA)?
– Does very low-dose dexamethasone therapy result in changes in babies’ neonatal growth?
3. Will it be possible to perform a large multicentre randomised controlled trial to assess the 2-year
neurodevelopmental outcomes of treatment with very low-dose dexamethasone?
4. Is a novel assessment of the family’s involvement with their baby feasible?
5. Does very low-dose dexamethasone affect changes in babies’ biochemical inflammatory
cytokine profile?
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The main part of the Methods chapter describes, in the interests of transparency, the study as planned.
The final paragraphs of the chapter describe events during the trial and the adaptations that were made to
the methods and analysis to respond to these events.
Trial design
This was a multicentre, randomised, masked, parallel-group, placebo-controlled Phase 2b trial to examine
the efficacy of very low-dose dexamethasone in facilitating the extubation of ventilator-dependent preterm
babies.
The trial was designed as a feasibility study for a subsequent study of the clinical effectiveness of very
low-dose dexamethasone in reducing the incidence of BPD at 36 weeks’ PMA. As such, the trial had a
surrogate outcome as a primary aim but collected information about a range of clinical outcomes and trial
characteristics to support the planning of a subsequent trial.
Babies were randomised in a one-to-one ratio to receive either a very low dose of dexamethasone or a
matched placebo. Allocation was masked from the baby’s family, the clinical team, the research team and
the statistical analysis team.
The trial was anticipated to take 30 months to complete and aimed to recruit, over 18 months, a total of
94 babies in up to 25 sites across the UK.
Parents of babies recruited at Leeds General Infirmary, Bradford Royal Infirmary and Hull Royal Infirmary
were asked to consent to their baby having samples taken for cytokine estimation to allow the modelling
of the babies’ inflammatory networks.
In addition, a novel diary to capture family experiences was piloted.
The trial flow diagram is shown in Figure 1.
Trial registration
The study is registered with the International Standard Randomised Controlled Trial Number (ISRCTN)
registry as number ISRCTN81191607.
Ethics and research governance approval
The protocol was reviewed by the North West – Liverpool Central Research Ethics Committee (REC) that
gave a favourable opinion (REC reference number 16/NW/0396).
The sponsor was the University of Liverpool (sponsor ID: UoL001206).
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Eligibility criteria Exclusion criteria
• Born at < 30 weeks’ gestation
• Aged between 10 and 24 postnatal days
   (≥ 10 and ≤ 24 postnatal days)
• At high risk of developing BPD: receiving
   mechanical ventilation via an endotracheal
   tube with at least 30% inspired oxygen when
   the PEEP is at least 4 cmH2O and, in the
   opinion of the treating physician, unlikely to
   be extubated within 48 hours
• Receiving caffeine therapy
• Written informed parental consent
• Born to a mother aged ≥ 16 years
• Postnatal steroid treatment for prevention or
   treatment of respiratory disease
• No realistic prospect of survival
• Severe congenital anomaly affecting the
   lungs, heart or central nervous system
• Surgical abdominal procedure or PDA
   ligation
• Illness or medications for which postnatal
   corticosteroid would be contraindicated
• Participation in another trial that would
   preclude the baby from inclusion in the
   Minidex
• Time to first extubation after first IMP dose (whether or not > 24 hours)
• Extubation by day 7a (when the baby remained extubated for > 24 hours)
• Extubation by day 7a (whether or not the baby remained extubated for > 24 hours)
• Survival to 36 weeks’ PMA
• Markers of respiratory morbidity to 36 weeks’ PMA (or discharge if sooner), as listed in the protocol
• Safety outcomes to 36 weeks’ PMA (or sooner if discharged home), as listed in the protocol
• Parent/family experience








Web-based randomisation (1 : 1 ratio) hosted by NPEU Clinical Trials Unit
Dexamethasone
(50 µg/kg per day every day for 10 days, 
then on alternate days for 6 days)
or 0.9% saline
(same volume administered daily for
10 days, then on alternate days for 6 days)
Time to first extubation after first IMP dose
(when the baby remains extubated for > 24 hours)
Metrics of feasibility: recruitment, retention, adherence to protocol and ascertainment of outcomes
FIGURE 1 Trial flow diagram. a, References to ‘day 7’ refer to 7 completed days from the first Investigative
Medicinal Product (IMP) dose. NPEU, National Perinatal Epidemiology Unit; PDA, patent ductus arteriosus;
PEEP, positive end-expiratory pressure.
METHODS





l babies born at < 30 weeks’ gestation
l babies aged between 10 and 24 postnatal days (i.e. ≥ 10 and ≤ 24 postnatal days)
l babies at high risk of developing BPD – receiving mechanical ventilation, via an endotracheal tube,
receiving at least 30% inspired oxygen when the positive end-expiratory pressure is at least 4 cmH2O
and, in the opinion of the treating physician, unlikely to be extubated within 48 hours
l babies receiving caffeine therapy
l written informed parental consent
l babies born to a mother aged ≥ 16 years.
Exclusion criteria
Exclusion criteria included babies:
l receiving postnatal steroid treatment for prevention or treatment of respiratory disease
l with no realistic prospect of survival
l with a severe congenital anomaly affecting the lungs, heart or central nervous system
l having undergone a surgical abdominal procedure or patent ductus arteriosus (PDA) ligation
l who are ill or receiving medication for which postnatal corticosteroid would be contraindicated
(e.g. an active fungal infection, confirmed or suspected acute sepsis, acute NEC/focal intestinal
perforation or cyclo-oxygenase therapy)
l participating in another trial that would preclude the baby from inclusion in the MINIDEX feasibility trial.
Setting
The trial took place in neonatal units across the UK.
Recruiting sites were tertiary neonatal units that screened potential participants, undertook recruitment,
randomised participants, and started trial procedures and administration of Investigative Medicinal Product
(IMP) (n = 11; see Appendix 1).
Sites were secondary or tertiary neonatal units that completed trial procedures if participants were
transferred from recruiting sites for clinical reasons (n = 26; see Appendix 2).
When more than one trial was open in a recruiting site, the potential for co-recruitment was discussed
between the Chief Investigator and Clinical Lead of the MINIDEX study, and the leaders of other trials.
Participants could be co-recruited to the following trials: ELFIN (Enteral LactoFerrin In Neonates), PlaNeT-2
(Platelets for Neonatal Transfusion – study 2), PREVAIL (PREVenting infection using Antimicrobial Impregnated
Long lines), SPRING (Sustainable PRogramme Incorporating Nutrition and Games (for maximising development,
growth and survival) and REACT (Real Time Continuous Glucose Monitoring in the Newborn). Participants
could not be co-recruited to Baby-Oscar (Outcome after Selective Early Closure of PDA) and Firefly.
Screening and recruitment
A daily review of the baby’s status allowed the attending clinical team, at recruiting sites, to identify babies
who were likely to be eligible for the trial. Trial eligibility was confirmed by a medically qualified clinician
who was on the delegation log.
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Once a baby had been identified as eligible, a full verbal and written explanation of the trial (via the Parent
Information Leaflet) was provided for the parents to consider. Parents who did not speak English were
approached only if an unrelated adult interpreter was available.
Following provision of information about the trial, parents had time to consider participation and were
given the opportunity to discuss the trial with their family and health-care professionals before they were
asked whether or not they would be willing to take part in the trial.
When parents of eligible babies were happy for the babies to participate, the parents provided informed
written consent by means of a dated signature.
Randomisation
Randomisation was managed via a secure web-based randomisation facility hosted by the National
Perinatal Epidemiology Unit (NPEU) Clinical Trials Unit (CTU), at the University of Oxford, with telephone
backup available all at times (i.e. 24/7, 365 days a year). The randomisation program used a minimisation
algorithm to ensure balance between the trial groups, with respect to collaborating hospital, sex, multiple
births, gestational age at birth and existing diuretic therapy for the 24 hours prior to randomisation. Babies
from multiple births were randomised individually.
Cytokines
Parents of babies recruited at specified sites were asked to consent to having opportunistic microsamples
of blood and endotracheal tube secretions taken at study entry, and within the 4-hour period prior to the
IMP dose on days 4, 7, 10 and 14 after randomisation.
A maximum of 0.5 ml of blood (total blood volume of 1.5 ml, to a maximum of 2.5 ml over the 14 days)
was obtained as an ‘extra sample’ by trained staff at the time of a clinically indicated capillary blood
sampling episode on these five occasions. Endotracheal tube secretions were obtained at the time of
clinically indicated endotracheal tube suction (in ventilated babies only). The endotracheal tube suction was
performed by trained staff.
Cytokine profiling
The cytokine analysis has yet to be performed. Cytokines will be profiled in plasma and endotracheal tube
secretions by multiplex immunoassay (Bio-Plex Pro™; Bio-Rad, Laboratories, Inc., Hercules, CA, USA) on
a Luminex® 200™ System (Luminex Corporation, Austin, TX, USA) cytometer equipped with Bio-Plex
Manager software (version 6.11; Bio-Rad, Laboratories, Inc.).28 The following multiplex immunoassay kits
will be used:
l Bio-Plex Pro Human Cytokine 21-plex Assay (#MF0005KMII; Bio-Rad, Laboratories, Inc.). Analytes to be
examined include interleukin (IL) 1 alpha (IL-1α), IL-2 receptor alpha (IL-2Rα), IL-3, IL-12 (specifically the
p40 subunit of IL-12), IL-16, IL-18, CTACK (cutaneous T cell-attracting chemokine), growth-related
oncogene (GRO) alpha (GRO-α), hepatocyte growth factor (HGF), interferon (IFN) alpha 2 (IFN-α2),
leukaemia inhibitory factor (LIF), monocyte chemoattractant protein (MCP) 3 (MCP-3), macrophage
colony-stimulating factor (M-CSF), macrophage migration inhibitory factor (MIF), monokine induced by
gamma interferon (MIG), β-nerve growth factor (NGF), stem cell factor (SCF), stem cell growth factor
(SCGF) beta (SCGF-β), stromal cell-derived factor (SDF) one alpha (SDF-1α), tumour necrosis factor (TNF)
beta (TNF-β) and TNF-related apoptosis-inducing ligand (TRAIL).
METHODS
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l Bio-Plex Pro Human Cytokine 27-plex Assay (#M500KCAF0Y; Bio-Rad, Laboratories, Inc.). Analytes to be
examined include basic fibroblast growth factor (bFGF), eotaxin, granulocyte colony-stimulating factor
(G-CSF), granulocyte–macrophage colony-stimulating factor (GM-CSF), IFN gamma (IFN-γ), IL 1 beta
(IL-1β), IL-1 receptor antagonist (IL-1RA), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (specifically the
p70 subunit of IL-12), IL-13, IL-15, IL-17, IFN-γ-induced protein 10 (IP-10), MCP 1 (MCP-1), methyl
CpG-binding domain protein 1 (MBD1)-containing chromatin-associated factor (MCAF), macrophage
inflammatory protein (MIP) one alpha (MIP–1α), MIP 1 beta (MIP-1β), platelet-derived growth factor
(PDGF) two B subunits (PDGF-BB), regulated upon activation, normal T cell expressed and secreted
(RANTES), TNF alpha (TNF-α) and vascular endothelial growth factor (VEGF).
Plasma samples will be diluted in accordance with the manufacturer’s recommendations. For the endotracheal
tube secretions, a small aliquot (i.e. 20 µl) will be set aside for protein concentration determination in order
to standardise cytokine concentrations to total protein given the dilutional effect in the collection of these
specimens.
Sample size and power
For the primary outcome of time to extubation, assuming 90% power and two-sided 5% level of significance,
a log-rank test with a sample size of 70 babies (35 in each trial arm) was required to detect a HR of 2.3 for a
control group HR of 1.0. This HR is the lower end of the CI found by the retrospective study (adjusted HR
6.24, 95% CI 2.34 to 16.63).25 This sample size allowed for the detection of a clinically important absolute
risk reduction of 36% for the secondary outcome of failure to extubate by day 7 of the intervention
period, with 90% power, a two-sided 5% level of statistical significance, and a control group incidence of
80%. (This is consistent with control group event rates reported in previous trials.25,26) As other previously
published randomised trials of dexamethasone report failure to extubate by day 7 as a primary outcome, it
was considered in this study an important secondary outcome to consider in the sample size calculations.
As all centres routinely collect the required data, a negligible loss to follow-up was anticipated. However, as
the primary analysis was per protocol, babies were censored for the primary outcome (and other time-to-event
outcomes) if the baby either died, if treatment was discontinued before extubation or if the baby remained
intubated at day 16 (i.e. the last day of the intervention period). These babies were excluded from the analysis
of other secondary outcomes.
Studies and published data sets show that 13.5–18% of babies < 30 weeks’ gestational age have late-onset
sepsis;2,29 7% will be treated for NEC;1 and 14% will be treated for PDA with cyclo-oxygenase inhibitors.30
It was estimated that one-third of late-onset sepsis, half of NEC and one-quarter of treated PDA would
occur in the study period. Therefore, it was expected that in up to 14% of babies the study treatment would
be permanently discontinued for clinical reasons. It was estimated that 10% of babies would either die before
extubation or remain intubated at day 16. Deaths were reported to the Data Monitoring Committee (DMC),
which monitored for any safety imbalances or differences in censoring rates between the trial groups.
The per-protocol analysis assumed that approximately 23% of all babies would be censored or excluded,
giving a final overall sample size target of at least 94 babies.
Cytokine profile sample size
With regard to the secondary outcome of inflammatory network modelling, the samples obtained from
specified sites (approximately 16 babies) would be sufficient for detecting differences in absolute cytokine
concentrations. This assumption was based on work conducted in the assisted conception setting rather
than power calculations, as the principal purpose of measuring cytokines in the current context is not to
determine changes in individual cytokines, but rather to understand differences in network evolution in
relation to response to dexamethasone and those characterising BPD.
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Interventions
Dexamethasone (Hospira, Lake Forest, IL, USA; 3.3 mg/ml solution of dexamethasone for injection) was
supplied as a clear sterile solution at a concentration of 3.3 mg per 1 ml in 2-ml vials. Cartons containing
14 single-use vials were provided.
Doses of 50 µg/kg (0.015 ml/kg of 3.3 mg/ml solution) dexamethasone were administered daily on days
1–10 after randomisation (i.e. 10 doses), then on alternate days (i.e. on days 12, 14 and 16), making a total
of 13 doses. Doses were calculated on the current working weight of the baby at the time of randomisation
(but could be increased in line with subsequent working weight as per local practice) and diluted to the
appropriate volume with dextrose or saline. The current working weight was designated by individual units
as the weight to manage IMPs with. While the baby had an intravenous line in situ (peripheral or central),
each dose was given as a short intravenous infusion over 10–15 minutes. Once intravenous access had been
removed, the IMP could be given via the nasogastric tube or orally. The doses were prepared and diluted in
the same manner for oral, nasogastric and intravenous administration.
All 13 doses were given unless there was an adverse effect necessitating stoppage, as described below.
The placebo was supplied as a clear sterile solution of 0.9% saline solution for injection. Cartons identical
to those for dexamethasone, each containing 14 identical single-use vials, were provided. The volume of
IMP to be withdrawn from the vial was calculated following the calculations for dexamethasone dosing
and then diluted with dextrose or normal saline for administration.
Supplies of the active product and placebo were prepared in a Medicines and Healthcare products
Regulatory Agency (MHRA)-recognised manufacturing facility at Guy’s and St Thomas’s NHS Foundation
Trust (London, UK). The active product and placebo were released by the qualified person (i.e. QP released).
Open-label treatment
If the clinical condition of a baby warranted intervention, treatment with open-label corticosteroids after
the intervention period could be given and was recorded.
Stopping trial medications
Trial medications could be stopped under the following circumstances:
1. parental wish
2. intolerable adverse reaction to study drug, as determined by the treating clinician (e.g. anaphylaxis)
3. requirement for cyclo-oxygenase therapy
4. if deemed by the treating clinician to be in the baby’s best interest (e.g. overwhelming sepsis or need
for open-label corticosteroid).
If the trial medication was stopped, data were collected for the remainder of the trial. No further blood
and bronchoalveolar samples were taken if the baby was participating in the cytokine substudy. Samples
that were taken inadvertently after the IMP was stopped were analysed.
When parents chose to withdraw their baby from the trial, permission was sought to continue data
collection and/or use data up to the point of withdrawal from the trial.
METHODS
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Parent diary
Being actively involved in the baby’s day-to-day care and having contact with their child is an important
part of both parental bonding and baby development. The parent diary was developed in conjunction with
the parents who provided patient and public involvement (PPI) to the trial. It was designed to capture
details about the amount of contact and interaction the family were able to have with their baby during
administration of the IMP. The way the family felt the baby reacted to their contact was recorded. It was
hoped that this would allow an assessment of the impact of the treatment on the family and their
experience of the baby’s neonatal journey to be made. The diaries were trialled by a group of parents
whose babies were receiving intensive care, and were found to be easy to use.
Parents were invited to complete a daily log of their interactions with their baby. Interactions were divided
into ‘cares’ and ‘contact and cuddles’. ‘Cares’ was the amount of parental involvement in the day-to-day
care of a preterm baby, such as nappy changes and mouth care. Contact and cuddles were the amount of
time the family were able to spend holding the baby. The degree of contact the baby could tolerate was
graded from the least contact of hand-holding to the full contact of skin-to-skin, when the baby is placed
inside the parent’s clothing for a cuddle.
Outcomes
The objectives and outcomes are described in Table 2. Further details of the severity criteria used to
determine the secondary outcome of BPD are included in Appendices 3 and 4.
The trial schedule is shown in Table 3.
TABLE 2 Trial objectives, outcome measures and time points of evaluation
Objectives Outcome measures
Time point(s) of evaluation
of this outcome measure
(if applicable)
Primary objective
To determine if treatment with very low-dose
dexamethasone facilitates the extubation
(for > 24 hours) of ventilator-dependent
preterm babies of < 30 weeks’ gestation who
are at high risk of developing BPD
Time to first extubation after first
IMP dose when the baby remains
extubated for > 24 hours
Secondary objectives
To determine if the treatment of ventilator-
dependent preterm babies of < 30 weeks’
gestation who are at high risk of developing
BPD with very low-dose dexamethasone
impacts upon:
1. Time to first extubation (whether or not
> 24 hours)
Time to first extubation after
first IMP dose (whether or not
> 24 hours)
2. Extubation by day 7 (a) Extubation within 7 completed
days after the first IMP dose
(where the baby has remained
extubated for > 24 hours)
(b) Extubation by day 7 of the
intervention period (whether or
not > 24 hours)
Day 7 of the intervention period
continued
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TABLE 2 Trial objectives, outcome measures and time points of evaluation (continued )
Objectives Outcome measures
Time point(s) of evaluation
of this outcome measure
(if applicable)
3. Survival to 36 weeks’ PMA Alive at 36 weeks’ PMA
(or discharge home if sooner)
36 weeks’ PMA (or discharge
home if sooner)
4. Respiratory morbidity to 36 weeks’ PMA
(or discharge home if sooner)
(a) Total duration of invasive
ventilation through
endotracheal tube
(b) Total duration of non-invasive
respiratory support through
nasal CPAP, nasal ventilation or
high-flow oxygen therapy
(c) Open-label treatment using
local unit policy, i.e. escalation
of corticosteroid therapy or
requirement for repeated
courses of corticosteroid
(d) Use of diuretics using local
unit policy
(e) Total duration of supplemental
oxygen therapy
(f) Severity of BPD at 36 weeks’ PMA
(or discharge home if sooner), as
defined in Appendix 3. Oxygen
requirement will be determined
using the oxygen reduction test
(see Appendix 4)
36 weeks’ PMA (or discharge
home if sooner)




perforation or NEC [definitive
and/or complicated (i.e. Bell




(e) Deterioration in cranial
ultrasound findings. A new
finding of severe IVH (grade III/IV
with ventricular dilatation or
intraparenchymal bleeding)
or new PVL on the CrUSS,
performed at 36 weeks’ PMA
(± 2 weeks), when compared
with the scan performed most
recently prior to randomisation
(f) Growth:
– Change in SDS for weight
between study entry and day
14 after randomisation
– Change in SDS for weight
between day 14 after
randomisation and 36 weeks’
PMA (or discharge home
if sooner)




study entry and 36 weeks’
PMA (or discharge home
if sooner)
During administration of IMP
and for 14 days after last dose
of intervention (a–d)
CrUSS performed prior to
randomisation (or when
occurring according to standard
clinical practice) and at 36 weeks’
PMA ( ± 2 weeks or discharge
home if sooner)
Weight measured at trial entry,
on day 14 (after randomisation)
and 36 weeks’ PMA ( ± 2 weeks
or discharge home if sooner)
Head circumference measured at
trial entry, and at 36 weeks’ PMA
( ± 2 weeks or discharge home if
sooner)
METHODS
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Hypothesis to be tested
To determine if the treatment with very low-dose dexamethasone of ventilator-dependent preterm babies
of < 30 weeks’ gestation who are at high risk of developing BPD impacts upon:
1. time to extubation (where the baby remains extubated for > 24 hours)
2. time to extubation (whether or not the baby remains extubated for > 24 hours)
3. rates of extubation by day 7 of the intervention period (where the baby remains extubated for
> 24 hours)
4. rates of extubation by day 7 of the intervention period (whether or not the baby remains extubated
for > 24 hours)
5. survival to 36 weeks’ PMA (or discharge home if sooner)
6. respiratory morbidity to 36 weeks’ PMA (or discharge home if sooner)
7. cytokine profile
8. safety outcomes
9. the parent/family experience.
TABLE 2 Trial objectives, outcome measures and time points of evaluation (continued )
Objectives Outcome measures
Time point(s) of evaluation
of this outcome measure
(if applicable)
6. Parent/family experience Parent/family experience:
(a) Measures of the parents’/
family’s hands-on involvement
in their baby’s care
(b) Duration, frequency and
amount of contact with
their baby
(c) Degree of parental/family
involvement in care (nappy
changes, skin care, etc.)
Log recorded during 16-day
intervention period. Although
part of the consent process, this
is not part of the source data set
and is optional for parents and
staff to complete
Exploratory objective
Cytokine profile (consenting babies from
specified sites only)
Changes to the inflammatory
cytokine profile in blood and
endotracheal tube secretion fluid
(a mechanistic marker of response)
Endotracheal tube secretions
and blood samples taken at trial
entry, and on days 4, 7, 10 and
14 of the IMP administration
schedule
Tertiary objectives
To assess the acceptability and feasibility of
the trial in order to inform the design of the
subsequent effectiveness trial by reporting
metrics related to:
1. Recruitment Recruitment rate Trial completion
2. Retention Retention rate Trial completion
3. Adherence to protocol Use of open-label therapy and
completion of course
Trial completion
4. Completeness of data Ascertainment of outcomes Trial completion
CPAP, continuous positive airway pressure; CrUSS, cranial ultrasound scan; IVH, intraventricular haemorrhage;
PVL, periventricular leukomalacia; SDS, standard deviation score.
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Adverse reactions and adverse events
The Reference Safety Information for pharmacovigilance purposes was the Summary of Product
Characteristics for the 3.3 mg/ml dexamethasone product, which was manufactured by Hameln
Pharmaceuticals Ltd (Gloucester, UK).
Serious adverse events and serious adverse reactions that were anticipated in the trial population were
reported on the case report form (CRF).
Other serious adverse events (SAEs) and serious adverse reactions were reported in an expedited manner
to NPEU.
The NPEU CTU reviewed each report, requested any additional information and ensured that it was assessed
by the Chief Investigator (or their delegate) within the reporting time frame for potential suspected
unexpected serious adverse reactions.
Statistical analysis
Demographic factors, clinical characteristics, and service utilisation were summarised with counts
(percentages) for categorical variables, mean [standard deviation (SD)] for normally distributed variables
and median [interquartile range (IQR) or other percentile range] for other continuous variables.
The original statistical analysis plan entailed calculating the HR plus 95% CIs for the primary outcome,
the risk ratio (plus 95% CI) for dichotomous outcomes, and the mean or median difference (plus 95% CI)
for other continuous variables. As this was an efficacy study, the plan was to base the primary inference on
a per-protocol analysis, excluding babies who were discontinued from the study treatment. For time-to-event
analyses, babies who discontinued or died before extubation or who remained intubated at day 16 would
have been censored.
The plan was to conduct a secondary analysis of all outcomes on an intention-to-treat basis. There was
also a preplanned subgroup analysis to examine the consistency of the effect of dexamethasone on the
primary outcome using the statistical test of interaction across the following subgroups: (1) gestational
age, (2) singleton versus multiple pregnancy and (3) diuretic use at trial outset.
Analysis of cytokine data
Basic cytokine data analysis would be largely conducted using a combination of Kruskal–Wallis and
post hoc Dunn’s tests. Significance levels would be corrected for multiple comparisons by applying Holm’s
sequentially selective Bonferroni method. Thereafter, correlation, principal components and factor analyses
would be used as recognised tools to investigate mediator inter-relationships. More informative network-
based approaches would be used to model inflammatory cytokine–cytokine network interactions using
Bayesian methods refined in-house. These networks offer a framework combining uncertainty (probabilities)
and logical structure (independence constraints) to represent complex biological phenomena by generating
acyclic graph-based models of joint probability distributions representing the conditional independence
between related variables.31 The key element of this approach is that this allows investigators to capture
the complex biological features of cytokines, such as antagonism, synergy and functional redundancy, as
recently shown by Beal et al. [rather than relying on the increasingly inadequate T helper (Th) cell type 1/2
(Th1/Th2) paradigm].31
Two dichotomisations would be applied: one in response to dexamethasone therapy versus placebo and
one relating to the time to extubation (groupings for the latter will be determined empirically based on the
DOI: 10.3310/eme06080 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 8
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Yates et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
data emerging from the study), independent of treatment. Both will incorporate a dynamic aspect to the
Bayesian model to account for changes in cytokine profiles and inter-relationships over time. Data from
each group will also be used to develop modified variational Bayesian state–space models (in which the
human-specific text-learning algorithm will be used; https://compbio.dfci.harvard.edu/predictivenetworks/)
to generate prior networks. Initialisation fields will be set to 10 seeds and 1000 iterations, and the
maximum hidden-state dimension limited to 20. A z-score equivalent to a 98% significance threshold will
be used to define the number of edges reaching significance. Networks will be visualised using either the
open-source platform Cytoscape (https://cytoscape.org; 24 May 2019) or the open-graph Viz platform,
Gephi (https://gephi.org; 24 May 2019). The spatialisation technique applied will be the force-directed
Yifan Hu algorithm, whereas a community detection algorithm will be used to detect the underlying graph
topology modular structure. It is also planned to use machine-learning-based methods in an attempt to
identify the value of specific small groups of cytokines as predictors of outcome by using a support vector
machine and a random forest-based combinatorial approach developed in-house. The main focus of these,
that is the cytokines, was to offer a starting point for an iterative stepwise empirical identification of
outcome predictors based on feature importance ranking.
Given the discontinuation of the trial, and the comparatively limited number of samples collected, it may
now not be possible to conduct a Bayesian-based analysis of the results.
Trial management
Project Management Group
The Project Management Group (PMG) supervised the trial on a day-to-day basis. The PMG comprised the
Chief Investigator, Lead Clinician, Trial Manager, Trial Statistician, Trials Programming Team, Senior Trials
Managers and CTU Director. PMG meetings were held every 6–8 weeks to provide regular central
monitoring of the trial, key items reviewed were recruitment, data monitoring reports, safety, incidents,
programming and statistical concerns, IMP stock management, and any other relevant topics such as
upcoming reports, oversight committee meetings, and amendments.
Trial Steering Committee
The members of the Trial Steering Committee (TSC) are included in Table 4.
Data Monitoring Committee
The members of the DMC are included in Table 5.
Public and patient involvement
A focus group of parents of ex-premature babies provided PPI input on the trial structure and assisted with
the development of the family-centred study outcomes. One member of this group was a trial co-applicant.
The member contributed to the development of the bespoke parent-facing trial materials, including the diary
of care.
Data management
All trial data were collected using bespoke CRFs and processed in line with the NPEU CTU standard
operating procedures.
Case report form entries were considered source data if the CRF is the site of the original recording
(e.g. there is no other written or electronic record of data, for example medical records). All documents
are stored safely in confidential conditions.
METHODS
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Minimal personal data were collected and stored at NPEU CTU. The infant’s name and any other identifying
details were stored separately and linked by the trial number. Data were stored in an electronic database in
which the participant was identified by a trial-specific number. This information will be stored for a period
not less than 25 years in order to follow up health-related issues that may become relevant in the future.
After the trial has been completed and the reports published, the data will be archived in a secure physical or
an electronic location with controlled access.
TABLE 4 Members of the TSC
Role Salutation and name Position of employment and institution
Independent chairperson Professor Henry Halliday Consultant Neonatologist, retired, Belfast, UK
Independent vice-chairperson Dr Gopi Menon Consultant Neonatologist, Simpson Centre for
Reproductive Health, Royal Infirmary of Edinburgh,
Edinburgh, UK
Independent Professor Howard Clark Consultant Neonatologist, Southampton General
Hospital, Southampton, UK
Independent Dr Paul Mannix Consultant Neonatologist, North Bristol NHS Trust,
Southmead Hospital, Bristol, UK
Independent Mrs Vanessa Lett PPI representative, Leicester, UK
Independent Mrs Nicola Kitchin PPI representative, Ashton-Under-Lyne, UK
Independent Ms Trish Hepburn Senior Statistician, Faculty of Medicine and Health
Sciences, Queen’s Medical Centre, Nottingham, UK
Non-independent Dr Helen Yates Clinical Lead, Consultant Neonatologist, Hull Royal
Infirmary, Hull, UK
Non-independent Dr Mark Turner Chief Investigator, Consultant Neonatologist, University
Department of Women’s and Child Health, Liverpool
Women’s and Children’s Hospital, Liverpool, UK
Non-independent Associate Professor Ed Juszczak NPEU Clinical Trials Unit Director, NPEU CTU,
University of Oxford, Oxford, UK
Observer Mrs Ursula Bowler Senior Trials Manager, NPEU CTU, University of Oxford,
Oxford, UK
Observer Dr Vaneesha Short MINIDEX Trial Manager, National Perinatal Epidemiology
Unit CTU, University of Oxford, Oxford, UK
Observer Ms Karen Wilding Research Integrity and Governance Manager, University
of Liverpool/Liverpool Joint Research Office, Liverpool, UK
TABLE 5 Members of the DMC
Role Salutation and name Position of employment and institution
Independent chairperson Professor Ben Stenson Consultant Neonatologist, Senior Lecturer, Neonatal
Unit, Simpson Centre for Reproductive Health, Royal
Infirmary of Edinburgh, Edinburgh, UK
Independent Professor Catherine Hewitt Deputy Director, Statistician, York Trials Unit,
University of York, York, UK
Independent Dr Chris Gale Senior Lecturer in Neonatal Medicine, Imperial College
London; Consultant Neonatologist, Chelsea and
Westminster NHS Foundation Trust, London, UK
Independent Professor Sailesh Kotecha Consultant in Paediatrics, Department of Health,
Cardiff University School of Medicine, Cardiff, UK
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Circumstances during the trial
The grant award start date was November 2015, with a planned recruitment start date of March 2016 and
recruitment completion date of August 2017. Trial set up took longer than anticipated and recruitment did
not commence until 21 July 2017.
The reasons for this 16-month delay were:
1. Change in trial sponsor.
Originally the MINIDEX trial was to be sponsored by Leeds Teaching Hospitals NHS Trust. All
documentation was prepared and submitted to Leeds Teaching Hospitals NHS Trust for review in this
role. The original contract between Leeds Teaching Hospitals NHS Trust and the Department of Health
and Social Care was signed on 28 August 2015. However, after a MHRA inspection it became clear to
Leeds Teaching Hospitals NHS Trust that it would not be in a position to continue with sponsorship.
After negotiations with the funder, the University of Liverpool agreed to take on sponsorship if the
Chief Investigator was changed to Dr Mark Turner, who is employed by the University of Liverpool.
The change of sponsor took a long time to facilitate and, ultimately, it was 21 October 2016 before the
Deed of Novation to transfer sponsorship to the University of Liverpool was sent to all parties. Research
agreements with recruiting sites could not be arranged and signed until the transfer of sponsorship was
complete, resulting in a significant delay to site initiation.
2. Sourcing matched components for the placebo.
Sourcing and preparing IMP supplies for release by the QP at Guy’s and St Thomas’ NHS Foundation
Trust Pharmacy Manufacturing Unit took over 18 months, rather than the 4 months in the study plan.
This delay arose from difficulties with sourcing placebo. The manufacturers of the active agent were not
able to supply empty vials because of fears about counterfeit medicines. When suitable vials were
located after a global search there were extensive difficulties with sourcing an appropriate seal for the
vial. After a global search a matching seal was identified, but it was not possible to sterilise the vials
with this seal. A seal that could be sterilised was found, but this seal did not provide a perfect match to
the seal used with the active agent. The study team conducted a risk analysis and decided the risk of
unblinding was sufficiently low to justify using an imperfectly matched seal. The sponsor agreed to this
method of working. The funder was informed, and the placebo was QP released on 20 July 2017.
Once the trial opened, the recruitment rate was lower than expected. The trial team contacted sites
frequently to identify issues and facilitate their work on recruitment, including protocol amendments.
The proportion of discontinuations was 55%; much higher than the 23% estimated in the sample size
calculation. This meant that the number of participants who could contribute to a time-to-event analysis
was reduced substantially. The rate of discontinuation could not be reduced partway through the trial
because the key reasons for discontinuation were the requirement of open-label steroids (in the opinion
of the treating clinician) and overwhelming sepsis (for which antibiotics would be contraindicated with the
active drug).
Towards the end of the contracted funding period the study team approached the funders for a no-cost
extension.
In April 2018, the funders notified the study team that an extension was not appropriate. The funders
reported that the study team had obtained a sufficient number of data sets to conduct the final analysis
of the primary outcome. Given the rate of recruitment it would not be a good use of resources to continue
recruitment and generate sufficient data sets to conduct the other study analyses.
The batches of trial supplies expired on 30 April 2018. In the absence of further funding it was not possible
to order new batches. Recruitment closed on 14 April 2018. The last evaluation of the final participant took
place on 24 June 2018. The database was locked on 4 September 2018.
METHODS
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Adaptations made during the trial
The study team made strenuous efforts to identify, and when possible, address the issues relating to trial
supplies, the recruitment rate and the discontinuation rate.
Revised statistical analysis
The statistical plan was revised because of the much reduced sample size. Although 22 babies were recruited,
the number of events for the primary outcome was much lower than this. A total of 14 participants were
censored (mainly as a result of a high rate of discontinuations of the study drug), so only eight participants
presented the event of interest for the time-to-event analysis. The main deviations from the analysis described
in the protocol were as follows:
l No comparative analyses were performed for any outcomes. Only descriptive statistics were to be
reported by trial arm.
l Outcomes were reported for all babies randomised minus post-randomisation exclusions.
l No confidence intervals or p-values were reported.
l There were no adjustments made for the minimisation factors used at randomisation or clustering
owing to multiple births.
l Subgroup analyses were not carried out.
l Exploratory analyses on the use of diuretics and oxygen in relation to treatment effect were not performed.
Time to first extubation outcomes were summarised with medians and IQRs. The number of babies in whom
the intervention was discontinued or who died before the event of interest occurred, and the number of
babies still intubated at day 16 was reported but not included in this summary measure. Extubation by day
7 outcomes were reported with counts and percentages. The numbers of babies who died or in whom the
intervention was discontinued before day 7 was reported and excluded from the denominator. Outcomes
recorded at 36 weeks’ PMA or discharge (if sooner), and safety outcomes, were reported for all babies
randomised and still alive at 36 weeks’ PMA or discharge. These outcomes were summarised with counts
(percentages) for categorical variables, mean (SD) for normally distributed variables and median (IQR) for
other non-normally distributed continuous variables.
Serious adverse events are listed, by allocation, for all babies randomised.
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The database was locked on 4 September 2018. The grant closed on 31 October 2018. Recruitmentstopped on 14 April 2018 after 22 babies, out of the planned sample size of 94, had been randomised
to the trial over a period of 9 months. This was a decision made by the funder owing to poor recruitment.
It was agreed that the final report should provide a descriptive analysis only because of the small number of
babies recruited to the trial.
Figure 2 presents the flow of participants in the trial. Among the 22 babies randomised, the intervention
was discontinued in 12 (see Table 13) and none was withdrawn from the trial. Maternal and neonatal
characteristics and all the outcomes are reported for all babies randomised. There were no post-randomisation
exclusions.
The participating units are shown in Table 6.
The maternal and neonatal characteristics of the participating babies are shown in Table 7. The primary
outcome is shown in Table 8 and Figure 3.












• Received dexamethasone, n = 12
• Full protocol, n = 6
• Discontinuations, n = 6
• Did not receive any dexamethasone,
   n = 0
Allocated to placebo
(n = 10)
• Received placebo, n = 10
• Full protocol, n = 4
• Discontinuations, n = 6
• Did not receive any placebo,
   n = 0
Not enrolled 
(n = 22)
• Parent(s) declined, n = 11
• Clinician decision, n = 9
• Unknown, n = 2
Eligible
(n = 44)
FIGURE 2 Flow of trial participants in the trial.
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TABLE 6 Participating units
Neonatal unit
Trial arm, n (%)
Dexamethasone Placebo
Hull Royal Infirmary 2 (16.7) 3 (30.0)
Leicester Royal Infirmary 1 (8.3) 2 (20.0)
Liverpool Women’s Hospital 3 (25.0) 0 (0.0)
Birmingham Women’s and Children’s NHS Foundation Trust 2 (16.7) 0 (0.0)
University Hospital Coventry 1 (8.3) 1 (10.0)
Bradford Royal Infirmary 1 (8.3) 1 (10.0)
Leeds General Infirmary 2 (16.7) 0 (0.0)
Royal Preston Hospital 0 (0.0) 2 (20.0)
Royal Victoria Infirmary (Newcastle upon Tyne) 0 (0.0) 1 (10.0)
Note
Two further units (Royal Hallamshire Hospital and North Tees Hospital) were also opened but were unable to recruit in the
study period.




Total number of babies 12 10
Maternal characteristics
Maternal age (years)
Median (IQR) 26 (21–31) 28 (23–34)
Mother’s ethnic group, n (%)
White 11 (91.7) 9 (90.0)
Mixed 0 (0.0) 0 (0.0)
Asian 1 (8.3) 0 (0.0)
Black 0 (0.0) 1 (10.0)
Arab 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0)
Unknown 0 (0.0) 0 (0.0)
Neonatal characteristics
Gestational age at birth (completed weeks)a
Median (IQR) 25 (24–25) 25 (23–26)
≤ 25, n (%) 10 (83.3) 7 (70.0)
26–27, n (%) 2 (16.7) 1 (10.0)
28–29, n (%) 0 (0.0) 2 (20.0)
RESULTS
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Number (%) of babies 10 (83.3) 7 (70.0)
< 4 hours before birth 2 (20.0) 1 (14.3)
≥ 4 hours before birth 8 (80.0) 6 (85.7)
1 dose 1 (12.5) 1 (16.7)
2 doses 4 (50.0) 4 (66.7)
> 2 doses 0 (0.0) 0 (0.0)
Not known 3 (37.5) 1 (16.7)
Time between rupture of membranes and birth, n (%)
< 24 hours 6 (50.0) 7 (70.0)
≥ 24 hours 4 (33.3) 3 (30.0)
Missing 2 0
Clinical chorioamnionitis evidence
Number (%) of babies 0 (0.0) 1 (10.0)
Level of neonatal unit at site of birth, n (%)
I 0 (0.0) 0 (0.0)
II 2 (16.7) 0 (0.0)
III 10 (83.3) 10 (100.0)
Other 0 (0.0) 0 (0.0)
Received diuretics for > 24 hours at randomisation, n (%)a
Number (%) of babies 3 (25.0) 2 (20.0)
Actual mode of delivery, n (%)
Vaginal delivery 10 (83.3) 6 (60.0)
Caesarean section 2 (16.7) 4 (40.0)
Baby’s sex, n (%)a
Male 8 (66.7) 4 (40.0)
Female 4 (33.3) 6 (60.0)
Indeterminate 0 (0.0) 0 (0.0)
Birth weight (g)
Mean (SD) 730.4 (175.1) 756.5 (191.1)
Birth weight centile
Mean (SD) 43.5 (32.5) 45.6 (20.1)
Birth weight centile cut-off points, n (%)
< Second centile 1 (8.3) 0 (0.0)
< Ninth centile 2 (16.7) 1 (10.0)
continued
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Postnatal age (days) at trial entry
Median (IQR) 13 (11–20) 16 (14–18)
10–14, n (%) 7 (58.3) 3 (30.0)
15–19, n (%) 2 (16.7) 6 (60.0)
20–24, n (%) 3 (25.0) 1 (10.0)
Multiple pregnancy, n (%)a
Singleton 11 (91.7) 8 (80.0)
Multiple 1 (8.3) 2 (20.0)
Birth order (only for multiple births), n (%)
First born 1 (100.0) 1 (50.0)
Second born 0 (0.0) 1 (50.0)
Third born 0 (0.0) 0 (0.0)
Temperature (°C) at admission to neonatal unit
Mean (SD) 36.8 (1.1) 37.4 (1.1)
Not recorded, n (%) 0 (0.0) 2 (20.0)
Worst base deficit in first 24 hours after birth
Mean (SD) 10.9 (5.7) 9.6 (5.1)
Apgar score at 5 minutes
Median (IQR) 5 (0–8) 5 (2–8)
Not recorded, n (%) 3 (25.0) 1 (10.0)
CRIB II score
Median (IQR) 15 (12–16) 15 (9–16)
Missing, n 0 2
CRIB score level I (1–5), n (%) 0 (0.0) 0 (0.0)
CRIB score level II (6–10), n (%) 1 (8.3) 3 (37.5)
CRIB score level III (11–15), n (%) 8 (66.7) 3 (37.5)
CRIB score level IV (> 15), n (%) 3 (25.0) 2 (25.0)
Ibuprofen treatment received before trial entry
Number (%) of babies 4 (33.3) 2 (20.0)
Air leak requiring chest drain before trial entry
Number (%) of babies 0 (0.0) 0 (0.0)
Hydrocortisone treatment received before trial entry
Number (%) of babies 2 (16.7) 0 (0.0)
Baby’s actual weight at trial entry (g)
Mean (SD) 862.1 (252.7) 851.1 (227.5)
RESULTS
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Head circumference (cm) at trial entryb
Mean (SD) 22.9 (1.5) 23.9 (2.6)
Missing, n 2 4
Ventilation method at trial entry, n (%)
IPPV 8 (66.7) 10 (100.0)
HFOV 4 (33.3) 0 (0.0)
FiO2 at trial entry (%)
Mean (SD) 49.8 (12.9) 41.2 (8.0)
Mean airway pressure (cmH20) at trial entry
Mean (SD) 8.9 (3.9) 11.5 (3.4)
Most recent cranial ultrasound results at trial entry (non-exclusive), n (%)
Cranial ultrasound not performed 1 (8.3) 0 (0.0)
No abnormality seen 4 (36.4) 7 (70.0)
IVH (worst on either side)
Grade I or II without ventricular dilatation 5 (45.5) 2 (20.0)
Severe IVH with ventricular dilatation (grade III) 0 (0.0) 1 (10.0)
IVH causing intraparenchymal bleeding (grade IV) 1 (9.1) 0 (0.0)
Hydrocephalus 0 (0.0) 1 (10.0)
PVL 0 (0.0) 0 (0.0)
Other white-matter injury 1 (9.1) 0 (0.0)
CRIB II, Clinical Risk Index for Babies scoring system II; FiO2, fraction of inspired oxygen; HFOV, high-frequency oscillatory
ventilation; IPPV, intermittent positive-pressure ventilation; IVH, intraventricular haemorrhage; PVL, periventricular
leukomalacia.
a Minimisation factors used to ensure balance at randomisation.
b Three head circumference measurements were taken > 5 days before randomisation.




Total number of babies 12 10
Censored (n) 6 8
Discontinuations (before/without extubation) 6 6
Did not have extubation criteria at day 16 0 2
Not censored/number of events 6 2
Time (hours) to first extubation after first IMP dose (if extubated for > 24 hours)
Median (IQR) 58.5 (47.9–91.5) 58.4 (47.3–69.5)
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The secondary outcomes are shown in Table 9.
The outcomes of the diary of care are shown in Table 10.
Safety outcomes are shown in Table 11, with SAEs presented in Table 12.
Details of the babies who discontinued the intervention are included in Table 13.
0
Kaplan–Meier failure estimates
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FIGURE 3 Kaplan–Meier failure estimates of the primary outcome.




Total number of babies 12 10
Censored, n 5 4
Discontinuations (before/without extubation) 5 4
Not been extubated by day 16 0 0
Not censored/number of events, n 7 6
Time (hours) to first extubation after first IMP dose (whether or not > 24 hours)
Median (IQR) 65.7 (47.9–91.5) 58.4 (18.3–123.4)
Extubation outcomes, n 8 6
Extubation by day 7 (extubated for > 24 hours), n (%)a 5 (62.5) 2 (33.3)
Extubation by day 7 (whether or not > 24 hours), n (%)a 5 (62.5) 4 (66.7)
Alive at 36 weeks’ PMA or discharge if sooner, n (%) 10 (83.3) 9 (90.0)
Total duration (days) of invasive ventilation through ET
Median (IQR) 23 (20–27) 31 (20–47)
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Total duration (days) of non-invasive respiratory support nasal CPAP, nasal ventilation or high-flow oxygen therapy
Median (IQR) 40 (27–50) 40 (28–46)
Total duration (days) of supplemental oxygen
Median (IQR) 15 (2 to 19) 4 (0 to 8)
Open-label treatment with corticosteroids received after randomisation
(cumulative dose), n (%)
5 (41.7) 8 (80.0)
< 1000 µg/kg 2 (40.0) 4 (50.0)
≥ 1000 µg/kg 3 (60.0) 4 (50.0)
Diuretics received for > 48 hours after randomisation, n (%) 8 (66.7) 9 (90.0)
Additionally received diuretics before randomisation 7 (87.5) 7 (77.8)
Did not receive diuretics before randomisation 1 (12.5) 2 (22.2)
BPD assessment at 36 weeks’ PMA or discharge if sooner, n (%) 10 9
No BPD 0 (0.0) 0 (0.0)
BPD 10 (100.0) 9 (100.0)
Mild 2 (20.0) 0 (0.0)
Moderate 2 (20.0) 2 (22.2)
Severe 6 (60.0) 7 (77.8)
CPAP, continuous positive airway pressure; ET, endotracheal tube.
a The denominators for the outcomes by day 7 exclude babies in whom the intervention was discontinued before day 7.




Total number of diaries of care returned 7 5
Time (days) to first cuddle
Median (IQR) 5 (4–6) 12 (2–22)
Missing 5 3
Time (days) to first skin-to-skin
Median (IQR) 4 (3–4) 2 (0–3)
Missing 5 3
Duration of contact (hours) a family member has with baby
Cuddle
Median (IQR) 13 (13–13) 2 (1–3)
Missing 6 3
continued
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Median (IQR) 15 (9–21) 9 (3–15)
Missing 5 3
Still touch
Median (IQR) 1 (0–1) 2 (0–3)
Missing 5 3
Containment
Median (IQR) 1 (0–11) 1 (0–3)
Missing 4 2
Frequency of contact a family member has with baby (number of contacts)
Cuddle
Median (IQR) 0 (0–1) 0 (0–1)
Missing 0 0
Skin-to-skin
Median (IQR) 0 (0–5) 0 (0–2)
Missing 0 0
Still touch
Median (IQR) 0 (0–1) 1 (1–1)
Missing 0 0
Containment
Median (IQR) 1 (0–2) 1 (0–2)
Missing 0 0
Average proportion of baby’s response to contact and cuddles
Well 81.0 47.0
Neutral 8.0 42.0
Not well 0.0 2.0
Missing 1 0
Time (days) to first family care
Median (IQR) 1 (1–4) 4 (1–15)
Missing 4 1
Frequency of family care in first week (number of contacts)
Median (IQR) 0 (0–6) 1 (0–5)
Missing 0 0
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Total number of babies 12 10
Hypertension, n (%) 0 (0.0) 1 (10.0)
Hyperglycaemia, n (%) 3 (25.0) 2 (20.0)
Sepsis, n (%)
Suspected 11 (91.7) 9 (90.0)
Received antibiotics for ≤ 72 hours 2 (18.2) 0 (0.0)
Received antibiotics for > 72 hours 9 (81.8) 9 (100.0)
Culture-positive sepsis 2 (22.2) 4 (44.4)
Did not receive antibiotics 0 (0.0) 0 (0.0)
Spontaneous gastrointestinal perforation or NEC
Total number (%) of babies 0 (0.0) 3 (30.0)
Spontaneous gastrointestinal perforation, n (%) 0 (0.0) 0 (0.0)
NEC, n (%) 0 (0.0) 1 (10.0)
Unclear, n (%) 0 (0.0) 2 (20.0)
Gastrointestinal haemorrhage (not associated with gastrointestinal perforation or NEC)
Total number (%) of babies 0 (0.0) 0 (0.0)
Clinically important deterioration in cranial ultrasound
Total number (%) of babies 1 (9.1) 1 (10.0)
Cranial ultrasound not carried out 1 0
New grade III for IVH 0 (0.0) 0 (0.0)
continued




Average proportion of baby’s response to contact and cuddles
Nappy changes 40.0 59.0
Skin cares 25.0 30.0
Mouth care 37.0 58.0
Missing 0 0
Average proportion of baby’s response to family care
Well 38.0 51.0
Neutral 3.0 17.0
Not well 2.0 12.0
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New grade IV for IVH 1 (100.0) 0 (0.0)
New PVL 0 (0.0) 1 (100.0)
New hydrocephalus 0 (0.0) 0 (0.0)
SDS for weight (g) at study entrya
Mean (SD) –1.1 (1.0) –1.4 (0.6)
Missing 0 0
SDS for weight (g) at day 14 after randomisationa
Mean (SD) –1.4 (1.1) –1.4 (0.8)
Missing 1 0
SDS for weight (g) at 36 weeks’ PMA (or sooner if discharged home)a
Mean (SD) –1.1 (1.0) –1.7 (1.0)
Missing 1 0
SDS for head circumference (cm) at study entrya
Mean (SD) –2.1 (0.9) –1.4 (0.8)
Missing 4 7
SDS for head circumference (cm) at 36 weeks’ PMA (or sooner if discharged home)a
Mean (SD)b –1.6 (1.0) –1.9 (1.1)
Missing 2 0
IVH, intraventricular haemorrhage; PVL, periventricular leukomalacia; SDS, standard deviation score.
a Standard deviation scores were calculated using the 2007 Application of WHO Growth Standards in the UK.32 These
standards indicate how far a baby is from the population mean weight and head circumference for babies of the same
age and sex.
b Includes one baby whose head circumference measurement was taken at 49 weeks rather than 36 weeks’ PMA.








ID Description Severity Outcome Causality
MI_10031 1 Active
(dexamethasone)
112 Hypoglycaemia Mild Resolved Not related
ID, trial identification number.
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This trial was not able to identify sufficient babies with the primary outcome to evaluate the study
objectives. The main metric of feasibility, recruitment, proved difficult. There was a tendency for open-label
medication and a higher than predicted rate of suspected/confirmed sepsis among babies. Recruitment
was halted following discussions with the TSC and the funder after 22 babies had been enrolled.
Findings
Baseline characteristics
The study groups were well balanced with regard to maternal and infant characteristics and no clinically
important imbalances were observed. There was a preponderance of babies born at < 25 weeks in both
arms of the trial and a lower than expected number of babies received antenatal steroids (77% as
opposed to the 86% predicted from national data sets).33 This appears to be indicative that the babies at
highest risk of remaining ventilator dependent, and being assessed as being at high risk of developing
BPD, are the most extremely preterm infants who do not receive protective antenatal interventions.
Efficacy
Owing to the low number of trial participants and the higher than predicted discontinuation rate it is possible
to comment only on possible trends seen at data analysis. It appears that very low-dose dexamethasone
may improve lung function and facilitate extubation.24,25 When compared with placebo, there was a higher
proportion of babies extubated at day 7 of life (62.5% in the dexamethasone group vs. 33.3% in the control
group) in addition to a reduced duration of invasive ventilation (median of 23 days in the dexamethasone
group vs. median of 31 days in the control group) in those babies treated with very low-dose dexamethasone.
In support of this finding is the trend to double the requirement for open-label rescue steroids in control
group babies (41.7% in the dexamethasone group vs. 80% in the control group).
Safety
Dexamethasone has been extensively researched in this population and its side effect profile is well identified.6,7
There were no unexpected safety concerns and no clinically important imbalances were observed.
Feasibility
All the clinical outcomes of the trial were ascertained appropriately; however, the trial was difficult to recruit
to as there was a lower than expected number of eligible babies. This may be due to a lack of clinician
equipoise, the inability to co-recruit to other key neonatal trials or changing neonatal practices.
The rate of discontinuation of the IMP for open-label steroids was higher than expected by the trial team
during trial planning, as was the rate of suspected sepsis, with 23% discontinuing for suspected/confirmed
sepsis as opposed to the predicted 6%. Discontinuation in favour of open-label steroids seems to represent
a loss of clinician equipoise regarding steroid therapy. The discrepancy in the predicted and actual rates of
sepsis is likely to reflect the fact that:
(a) The published data in this cohort are for confirmed culture-positive late-onset sepsis. Clinicians were
discontinuing on the grounds of suspected infection that, although the baby may manifest clinical
signs, may not result in positive blood cultures and so will be a more prevalent outcome.
(b) The babies selected for the trial are the most at-risk subset of babies and will consequently have a
higher than average risk of this outcome.
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Family diaries
Only 12 families (55%) completed and returned a diary of care. The completed diaries were incomplete
with large numbers of missing data for time to first cuddle, time to first skin-to-skin contact and duration
of contact a family member has with their baby.
Among the returned diaries it was notable that there were low values of frequency of contact a family
member had with the baby. It is uncertain whether this represents a true finding or incomplete data
collection.
Cytokines
The cytokine samples are yet to be analysed. Analysis will take place after the lifespan of the NIHR EME
programme funding.
Issues raised by this study
This study informs a number of discussion points relating to the evaluation of medicines to treat evolving
BPD.
Preparation of placebos for marketed products
The preparation of placebos for marketed products is a well-recognised problem. In the absence of
placebos for marketed products it will be impossible to evaluate existing treatments, many of which have
entered routine practice without appropriate evaluation. The unjustified use of legacy products is common
in paediatrics, particularly in neonates, and leads to the use of medicines that may not be effective, that
may have unrecognised safety concerns and that may not be an appropriate use of resources.
One way forward is to set up a centralised service to commission trial supplies. This could speed up the
process or pool expertise in making relevant judgements about the suitability of possible placebo
preparations.
Recruitment of neonates with evolving bronchopulmonary dysplasia to clinical trials
Although very low-dose dexamethasone had been in use in several centres throughout the UK, the cohort
study that formed the basis for planning the study was carried out in a single centre. That centre did not
have rates of BPD that differed from national norms.31 Since the cohort study was carried out, the rate of
BPD has not reduced markedly; however, clinicians’ attitudes to postnatal dexamethasone treatment are
changing and the ‘best practice’ care of extremely preterm babies is evolving as a result of the alterations
in the use of invasive and non-invasive respiratory support.34,35 The combination of these factors, in
addition to the inability to co-recruit to other concurrent neonatal trials, made it significantly more difficult
to recruit than anticipated. The proportion of parents of eligible babies approached regarding the trial who
gave consent was 66%, which is in line with experience in similar studies.36
It is speculated that the eligibility criteria do not match all the contemporary predictors of BPD. The patterns of
respiratory support currently given to neonates differ from past practice with respect to modes of support
during the initial stabilisation period after birth [i.e. nasal continuous positive airway pressure (CPAP); less
invasive surfactant administration] and/or subsequently (move to ‘early extubation’ with greater use of
volume-guaranteed ventilation or modes of non-invasive ventilation)35 facilitated by advances in technology
respiratory support. These changes in ventilation strategies have created a situation whereby babies at high
risk of developing BPD are not necessarily subjected to prolonged mechanical ventilation but may instead
be managed with non-invasive ventilation. This is a change since the cohort that informed the design of
this trial.
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To identify a cohort at high risk of developing BPD, it would now be necessary to adjust the threshold for
‘severity’ of respiratory support. The group of babies currently at risk of BPD is likely to include babies who
are receiving non-invasive ventilation. The wide variety of strategies and technology for respiratory support
of premature babies used throughout the UK poses difficulties in identifying both a homogeneous trial
group and a suitable surrogate outcome measure.
In the future, other novel ways of identifying ‘at-risk’ babies and surrogate outcomes, such as biomarkers,
may be useful, but need considerable development and are not yet ready for inclusion in clinical trials.
Discontinuation rates among neonates that participate in a trial of evolving
bronchopulmonary dysplasia
In total, treatment was discontinued in 12 babies (55%). This is more than double the 23% predicted at
trial planning.
Discontinuation related to clinician choice of open-label steroids occurred in six participants (27%). This
finding suggests that equipoise was not maintained with this dose. This may reflect changes in clinicians’
attitudes to postnatal steroid use.
Suspicion of sepsis that warranted discontinuation of steroids prompted discontinuation in trial
participation in five babies (23%). This is consistent with clinical practice in many centres and raises two
issues for the design of clinical trials about BPD:
1. Recruiting enough babies who are evaluable, that is, participants whose steroid treatment is not
discontinued because of clinical suspicion of infection.
2. How to study steroids in babies who start steroids more than once. This group needs to be studied
because most of the babies in whom steroids were discontinued will have had a subsequent course.
Indeed, a proportion of babies will start steroids three or four times. The effects of steroids may differ
according to the presence or absence of an infection (e.g. through a disturbance of the cytokine
milieu). This group of babies receiving ‘stop–start’ steroids could be studied through a preplanned
subgroup analysis of a trial that is powered according to the number of babies whose steroids are not
discontinued as a result of concerns about sepsis. An alternative approach would be a trial that is
powered to look at all babies who receive steroids. Planning a trial that includes ‘stop–start’ babies
would require careful consideration of the management of trial supplies.
Analysis of event rates in trials of evolving bronchopulmonary dysplasia
The very small number of events eligible for assessment of the primary outcome means that the trial was
not powered to detect a difference between the groups at the proposed HR of 6. Furthermore, although
this HR was quoted in the original application from a previous cohort study, it was considered by the study
team to be an extremely large effect size for a trial setting. The lower bound of the 95% CI for that HR
(2.3) was therefore used as a more realistic estimate to calculate the sample size of 94, as reported in
the MINIDEX trial protocol. Therefore, even if the trial continued to recruit until full data on ≈ 20 events
had been recorded (potentially ≈ 40–45 participants might need to be recruited for this because of
discontinuations and other exclusions), the trial would still only be powered to detect an implausibly high HR
of 6. The team are of the opinion that, even if recruitment continued to this number (≈ 40–45 participants),
there would not be enough power to detect a realistic difference in the primary outcome between the two
trial arms.
Description and partial validation of a novel parent reported outcome measurement
There was limited uptake of the parent-reported outcomes contained within the diary of care. It is unclear
whether this is a reflection of the design of the trial materials or the promotion of the diary by the sites or
whether or not it is a result of the variation seen in family engagement with trial processes.
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Although the diaries were incomplete, the data provided by those families who did engage with the
process suggest that it may be possible, with further refinements, to capture quantifiable data of the
way that clinical trials affect the family’s ability to parent and bond with their child. This is an important
family-centred outcome, championed by PPI, and ought to be part of the outcomes of other clinical trials.
Conclusions
Ultimately the trial addressed a particular question with a surrogate outcome in order to facilitate the
design of a definitive large pragmatic trial using substantive outcomes. The MINIDEX trial has served its
purpose and made clear that, in the contemporary clinical context, this approach to the research question
is not feasible. The research question remains open and will not be answered by the MINIDEX trial.
Other researchers are continuing to investigate other regimens of postnatal corticosteroid administration.
Following the PREMILOC (i.e. early administration of intravenous prophylactic hydrocortisone for the
prevention of BPD in extremely preterm babies) trial,37 Laboratoire Aguettant (Lyon, France) is developing
a formulation of low-dose hydrocortisone for neonates, with the intent to submit an application to the
European Medicines Agency, the US Food and Drug Administration, and Health Canada (Olivier Baud,
Hôpital universitaire Robert-Debré, Paris, YEAR, personal communication, 2018). The Eunice Kennedy
Shriver National Institute of Child Health and Human Development (NICHD) neonatal network is currently
conducting a trial of a higher dose of hydrocortisone tapered over 10 days starting between 14 and 28 days
in intubated babies born at < 30 weeks’ gestation.38 A trial recently published by the STOP-BPD study group
randomised 372 ventilator-dependent babies born at < 30 weeks’ gestation or with a birth weight under
1250 g to hydrocortisone or placebo at 7–14 days of life. Hydrocortisone was given as a 22-day tapering
course (cumulative dose of 72.5 mg/kg).39
The STOP-BPD trial found no differences between the groups for the either the composite outcome of BPD
and death (OR 0.87, 95% CI 0.54 to 1.38) or BPD (OR 1.24, 95% CI 0.82 to 1.86), leading the researchers
to conclude that hydrocortisone should not be used for this indication in these babies.39 The cumulative
dose of hydrocortisone used in the STOP-BPD trial had higher glucocorticoid potency than the cumulative
dose of dexamethasone used in MINIDEX trial.
As the incidence of BPD in the active treatment arm of the PREMILOC trial was 22% [as opposed to 26% in
the placebo arm, giving a RR of BPD 0.82 (95% CI 0.58 to 1.16)],37 there will continue to be a significant
number of babies who require ‘rescue corticosteroids’. The high dose of hydrocortisone on the NICHD
neonatal network trial may lead to a side effect profile that may be ameliorated by a lower glucocorticoid
dose. The dosage regimen used in STOP-BPD trial did not have an effect on outcomes.
Something needs to be done to optimise the use of steroids in evolving BPD.
Options include:
1. adjust recruitment to current practice – appropriate inclusion criteria
2. minimise rescue treatment – address equipoise among clinicians.
A better understanding of the biology and natural history of the condition will help. Routinely collected
data were not sufficient to adequately plan this study. Given the dynamic nature of neonatal care, novel
approaches are needed. These novel approaches could include registry-based trials or the use of enhanced
routine data collection to support trial planning.
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patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Recruiting sites
The recruiting sites in this feasibility trial were:
l Birmingham Women’s Hospital, Birmingham, UK
l Bradford Royal Infirmary, Bradford, UK
l Hull Royal Infirmary, Hull, UK
l Leeds General Infirmary, Leeds, UK
l Leicester Royal Infirmary, Leicester, UK
l Liverpool Women’s Hospital, Liverpool, UK
l Royal Hallamshire Hospital, Sheffield, UK
l Royal Preston Hospital, Preston, UK
l Royal Victoria Infirmary, Newcastle, UK
l University Hospital Coventry, Coventry, UK
l University Hospital of North Tees, Stockton-on-Tees, UK.
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Appendix 2 Continuing-care sites
The continuing-care sites in this feasibility trial were:
l Birmingham City Hospital, Birmingham, UK
l Birmingham Heartlands Hospital, Birmingham, UK
l Burnley General Hospital, Burnley, UK
l Calderdale Royal Hospital, Halifax, UK
l Chesterfield Royal Hospital, Chesterfield, UK
l Countess of Chester Hospital, Chester, UK
l Dewsbury and District Hospital, Dewsbury, UK
l Diana Princess of Wales Hospital, Grimsby, UK
l George Eliot Hospital, Nuneaton, UK
l Glenfield Hospital, Leicester, UK
l Harrogate District Hospital, Harrogate, UK
l James Cook University Hospital, Middlesbrough, UK
l Leicester General Hospital, Leicester, UK
l Lincoln County Hospital, Lincoln, UK
l Milton Keynes General Hospital, Milton Keynes, UK
l New Cross Hospital, Wolverhampton, UK
l Norfolk and Norwich University Hospital, Norwich, UK
l North Manchester General Hospital, Manchester, UK
l Pilgrim Hospital Boston, Boston, UK
l Pinderfields General Hospital, Wakefield, UK
l Pontefract Hospital, Pontefract, UK
l Queen’s Hospital, Burton on Trent, UK
l Royal Albert Edward Infirmary, Wigan, UK
l Royal Bolton Hospital, Bolton, UK
l Royal Oldham Hospital, Oldham, UK
l Wirral Women and Children’s Hospital, Wirral, UK.
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Appendix 3 Severity-based diagnostic criteria for
bronchopulmonary dysplasia
Time point of assessment: 36 weeks’ PMA
Therapy with oxygen > 21%
and/or
respiratory support for ≥ 28 days cumulatively
and
the following levels of oxygen requirement as determined by the oxygen reduction test:
Mild BPD Baby is breathing room air
Moderate BPD Baby is in 22–29% oxygen, or 0.01–1.0 l/minute
Severe BPD Baby is in FiO2 ≥ 30% or low-flow oxygen ≥ 1.1 l/minute or the baby is receiving respiratory support
(invasive or non-invasive) to achieve saturations of ≥ 91%
FiO2, fraction of inspired oxygen.
The need for oxygen will be determined by the oxygen reduction test. This is based on the minimum
inspired oxygen threshold at which the baby can maintain saturations of ≥ 91%. Babies requiring inspired
oxygen to maintain saturations of ≥ 91% are considered to be oxygen dependent.
The oxygen reduction test applies only to babies in < 0.3 inspired oxygen, or a low-flow oxygen of
< 1.1 l/minute, and who have not had respiratory support in the previous 24 hours. Those babies not
meeting these criteria will not be tested, but their oxygen requirements will be captured on the relevant
data form.
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Appendix 4 Oxygen reduction test
Oxygen reduction test
Only perform the oxygen reduction test if baby has received oxygen and/or respiratory support for ≥  28 days cumulatively
and the following:
• The baby is not receiving mechanical ventilation (invasive and non–invasive), CPAP or high-flow oxygen therapy
• FiO2 < 0.3 or low-flow oxygen <  1.1/m to maintain saturations of ≥ 91%
• In previous 24 hours baby has not required respiratory support
Has the baby received oxygen
and/or respiratory support










Is the baby still in oxygen?
Are their requirements:
FiO2 < 0.3 or low-flow oxygen < 1.1 l/m and
not receiving any respiratory support [mechanical
ventilation (invasive and non–invasive), CPAP or high flow
oxygen therapy] to achieve saturations of ≥ 91%
Reduce oxygen gradually to minimum level to be able to





Do not proceed with the test Do not proceed with the test
Baby in 22–29% oxygen
or 0.01–1.0 l/minute
moderate BPD
Baby is in air − 
mild BPD
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